Full genomes in hours vs. weeks - Single genome sequencing in hours greatly eases analysis bottlenecks (vs. batch-processing)
Ion Reporter Solution™ - Flexible cloud-based solution to manage, annotate, and archive variants of interest for future interpretation.
High Data Quality - More uniform coverage enables higher quality variant calls with less raw data. Longer reads enable a better mappability with less raw data.
http://www.invitrogen.com/site/us/en/home/Products-and-Services/Applications/Sequencing/Semiconductor-Sequencing/proton.html?CID=IonProton-SS-12612
In her recent publication “Fast isogenic mapping-by-sequencing of EMS-induced mutant bulks” in Plant Physiology, Dr. Franziska Turck and her team introduced deep candidate resequencing (dCARE) using the Ion PGM™ Sequencer to their Arabidopsis mutant identification pipeline.
These slides are from her Decmeber 5th live webinar presentation about the application of isogenic mapping approach for plant gene identification with fast and cost-effective barcoding using the Ion PGM™ system. She shared with the webinar attendees her experience with the ways that the Ion PGM™ system improves her deep sequencing workflow.
Learn more about the Ion Proton™ and Ion PGM™ here http://owl.li/g19ix
International Battery: Applying Lean Manufacturing Processes In The Productio...Charged2020
Antonio Reis, Vice President of Engineering, International Battery
• Implementing process validation to manufacturing processes to achieve efficiency, consistency and control
• Developing an innovative manufacturing process that provides robust key indicators for energy storage systems
cycle life
Review of CERN's objectives and how the computing infrastructure is evolving to address the challenges at scale using community supported software such as Puppet and OpenStack.
MicroCapClub Company Presentation: Acorn Energy (ACFN)Ian Cassel
Acorn Energy, Inc (ACFN), the digital energy company is a holding company focused on making energy better by providing digital solutions for energy infrastructure asset management. The four businesses in which we have controlling interests, improve the world's energy infrastructure by making it: more secure - providing security solutions for underwater energy infrastructure (DSIT); more reliable - providing condition-based monitoring to critical assets on the electric grid (GridSense, OmniMetrix) and more productive and efficient - increasing oil and gas production while lowering costs through use of permanent ultra-high sensitive seismic tools that allow for a more precise picture of reservoirs (US Seismic).
This is the first ever MicroCapClub company presentation featuring Acorn Energy (ACFN). Investors Neil Cataldi and DavidS join me while we listen and provide feedback to John Moore CEO of Acorn Energy. We hope you enjoy this medium, and we look forward to doing more interactive company presentations in the future with companies we find interesting.
Disclosures: ACFN is a sponsor of MicroCapClub. Ian Cassel, Neil Cataldi, and DavidS do not own shares of ACFN.
The MicroCapClub (mc2) is an exclusive micro cap forum focused on micro cap companies (sub $300m market cap). The MicroCapClub was created and founded by Ian Cassel as a way to share ideas and to learn from other seasoned like-minded micro cap investors. Our goal at MicroCapClub.com is quality membership and quality stock ideas. If you are an experienced micro cap investor, feel free to Apply today.
3D Perfusion Bioreactor Technical Presentation3D Biotek
The 3D Perfusion Bioreactor™ is manufactured by 3D Biotek, LLC, an innovative technology company based in North Brunwick, New Jersey. 3D Biotek launched the 3D Perfusion Bioreactor™ in 2011, as a novel alternative to integrate the need for innovative cellular maintenance and increasing trends towards 3-dimensional cell culture. The 3D Perfusion Bioreactor is engineered to perfuse porous 3D polymer Inserts™ in 4 separate polycarbonate chambers able to fit up to 10-scaffolds per chamber. The 3D Insert has been validated by NIST (National Institute of Standards) for its open-pore, ample surface area, and 100% interconnected geometry, important features for direct application in scale-up processes, from cell expansion to recombinant protein production.
The Nigeria Alternative Energy Expo 2012 is Nigeria’s leading alternative energy Expo. NAEE 2012 takes place at the Yaradua Convention Centre, Abuja Nigeria from September 17-19 2012. The event will feature an impressive line-up of local and international speakers, delegates and exhibitors, who will gather to debate a new energy future for Africa's most populous nation
An introduction to IO-Link. Gives an overview of how to add IO-Link to existing & new automation systems. By Neil Farrow, P.E. This is based on a presentation to ISA (the International Society for Automation).
The IoT Device is one of crucial point to choose solution.
See how IndoorPlus+ RTLS HW brings innovation in your needs.
The IndoorPlus + RTLS solution supports both dedicated hardware and compatible hardware.
However, when used with dedicated hardware, it shows best performance.
BLE tags used by the IndoorPlus+ RTLS solution are compatible with the iBeacon and protocol beacon, among others. These two tag beacons use dedicated BLE tags manufactured by PEOPLE AND TECHNOLOGY and have proven excellent performance.
The difference between performance of BLE tags for dedicated hardware and for compatible hardware is not a big.
The IndoorPlus+ RTLS solution can use the BLE chipset built in Wi-Fi AP or CCTV or the USB BLE scanner using the public USB interface.
Existing Wi-Fi AP or CCTV infrastructure can be used, with only the IndoorPlus+ gateway needing to be installed for shadow areas. This decrease overall Total Cost of Operation(TCO).
Moreover, the BLE gateways and scanner can be built for low cost using open hardware such as Raspberry, which has been successfully used by some of our customers such as Hotel Shilla and Amore-Pacific since 2015.
my students use ideas from my class on business models to develop a business model for ion proton's DNA sequencer. This sequencer uses semiconductor technology to read an organism's DNA sequence and is faster and cheaper than existing sequencers. This presentation describes the value proposition, customer selection, method of value capture and other aspects of a business model for Ion Proton's DNA sequencer
Hot-start DNA polymerases are commonly used in PCR for genotyping, sequencing, molecular diagnostics, and high-throughput applications. In this presentation, PCR performance of Invitrogen™ Platinum II Taq Hot-Start DNA Polymerase and Invitrogen™ AccuPrime Taq DNA Polymerase is compared in the following areas:
• PCR run time for targets of different lengths
• Amplification of AT-rich and GC-rich sequences
• Tolerance to PCR inhibitors
• Sensitivity in target detection
• Universal protocol for PCR targets of different lengths
• Multiplex PCR of 15 targets
• Product format for direct gel loading
Request a sample of Platinum II Taq enzyme at http://bit.ly/2M4U9cw
Find other PCR enzymes at http://bit.ly/2JIPrzj
Learn more about PCR at http://bit.ly/2y2aSVo
#PCR #PCREducation #Invitrogen #InvitrogenSchoolofMolBio
Human cytomegalovirus (CMV) is a common immune-evasive herpes family virus leading to lifelong asymptomatic infection in 50 to 80% of humans. Current research evaluating the use of
TCR sequencing to predict response to immunotherapy has focused on measurements of T cell clonal expansion and TCR convergence (2,3,4) as potential predictive biomarkers for
response. Given that CMV infection has been reported to elicit large clonal proliferations of CMV reactive T cells (1), and is a source of chronic antigen stimulation, we hypothesized that CMV
infection might alter T cell repertoire features in a manner relevant to the potential biomarker use of TCR sequencing. Here we sought to identify features of CMV infection using TCRB profiling of
peripheral blood (PBL) total RNA. We identify reduced T cell evenness and elevated TCR convergence as features of chronic CMV infection.
More Related Content
Similar to Ion Proton™ Sequencer - The Benchtop Genome Center
In her recent publication “Fast isogenic mapping-by-sequencing of EMS-induced mutant bulks” in Plant Physiology, Dr. Franziska Turck and her team introduced deep candidate resequencing (dCARE) using the Ion PGM™ Sequencer to their Arabidopsis mutant identification pipeline.
These slides are from her Decmeber 5th live webinar presentation about the application of isogenic mapping approach for plant gene identification with fast and cost-effective barcoding using the Ion PGM™ system. She shared with the webinar attendees her experience with the ways that the Ion PGM™ system improves her deep sequencing workflow.
Learn more about the Ion Proton™ and Ion PGM™ here http://owl.li/g19ix
International Battery: Applying Lean Manufacturing Processes In The Productio...Charged2020
Antonio Reis, Vice President of Engineering, International Battery
• Implementing process validation to manufacturing processes to achieve efficiency, consistency and control
• Developing an innovative manufacturing process that provides robust key indicators for energy storage systems
cycle life
Review of CERN's objectives and how the computing infrastructure is evolving to address the challenges at scale using community supported software such as Puppet and OpenStack.
MicroCapClub Company Presentation: Acorn Energy (ACFN)Ian Cassel
Acorn Energy, Inc (ACFN), the digital energy company is a holding company focused on making energy better by providing digital solutions for energy infrastructure asset management. The four businesses in which we have controlling interests, improve the world's energy infrastructure by making it: more secure - providing security solutions for underwater energy infrastructure (DSIT); more reliable - providing condition-based monitoring to critical assets on the electric grid (GridSense, OmniMetrix) and more productive and efficient - increasing oil and gas production while lowering costs through use of permanent ultra-high sensitive seismic tools that allow for a more precise picture of reservoirs (US Seismic).
This is the first ever MicroCapClub company presentation featuring Acorn Energy (ACFN). Investors Neil Cataldi and DavidS join me while we listen and provide feedback to John Moore CEO of Acorn Energy. We hope you enjoy this medium, and we look forward to doing more interactive company presentations in the future with companies we find interesting.
Disclosures: ACFN is a sponsor of MicroCapClub. Ian Cassel, Neil Cataldi, and DavidS do not own shares of ACFN.
The MicroCapClub (mc2) is an exclusive micro cap forum focused on micro cap companies (sub $300m market cap). The MicroCapClub was created and founded by Ian Cassel as a way to share ideas and to learn from other seasoned like-minded micro cap investors. Our goal at MicroCapClub.com is quality membership and quality stock ideas. If you are an experienced micro cap investor, feel free to Apply today.
3D Perfusion Bioreactor Technical Presentation3D Biotek
The 3D Perfusion Bioreactor™ is manufactured by 3D Biotek, LLC, an innovative technology company based in North Brunwick, New Jersey. 3D Biotek launched the 3D Perfusion Bioreactor™ in 2011, as a novel alternative to integrate the need for innovative cellular maintenance and increasing trends towards 3-dimensional cell culture. The 3D Perfusion Bioreactor is engineered to perfuse porous 3D polymer Inserts™ in 4 separate polycarbonate chambers able to fit up to 10-scaffolds per chamber. The 3D Insert has been validated by NIST (National Institute of Standards) for its open-pore, ample surface area, and 100% interconnected geometry, important features for direct application in scale-up processes, from cell expansion to recombinant protein production.
The Nigeria Alternative Energy Expo 2012 is Nigeria’s leading alternative energy Expo. NAEE 2012 takes place at the Yaradua Convention Centre, Abuja Nigeria from September 17-19 2012. The event will feature an impressive line-up of local and international speakers, delegates and exhibitors, who will gather to debate a new energy future for Africa's most populous nation
An introduction to IO-Link. Gives an overview of how to add IO-Link to existing & new automation systems. By Neil Farrow, P.E. This is based on a presentation to ISA (the International Society for Automation).
The IoT Device is one of crucial point to choose solution.
See how IndoorPlus+ RTLS HW brings innovation in your needs.
The IndoorPlus + RTLS solution supports both dedicated hardware and compatible hardware.
However, when used with dedicated hardware, it shows best performance.
BLE tags used by the IndoorPlus+ RTLS solution are compatible with the iBeacon and protocol beacon, among others. These two tag beacons use dedicated BLE tags manufactured by PEOPLE AND TECHNOLOGY and have proven excellent performance.
The difference between performance of BLE tags for dedicated hardware and for compatible hardware is not a big.
The IndoorPlus+ RTLS solution can use the BLE chipset built in Wi-Fi AP or CCTV or the USB BLE scanner using the public USB interface.
Existing Wi-Fi AP or CCTV infrastructure can be used, with only the IndoorPlus+ gateway needing to be installed for shadow areas. This decrease overall Total Cost of Operation(TCO).
Moreover, the BLE gateways and scanner can be built for low cost using open hardware such as Raspberry, which has been successfully used by some of our customers such as Hotel Shilla and Amore-Pacific since 2015.
my students use ideas from my class on business models to develop a business model for ion proton's DNA sequencer. This sequencer uses semiconductor technology to read an organism's DNA sequence and is faster and cheaper than existing sequencers. This presentation describes the value proposition, customer selection, method of value capture and other aspects of a business model for Ion Proton's DNA sequencer
Hot-start DNA polymerases are commonly used in PCR for genotyping, sequencing, molecular diagnostics, and high-throughput applications. In this presentation, PCR performance of Invitrogen™ Platinum II Taq Hot-Start DNA Polymerase and Invitrogen™ AccuPrime Taq DNA Polymerase is compared in the following areas:
• PCR run time for targets of different lengths
• Amplification of AT-rich and GC-rich sequences
• Tolerance to PCR inhibitors
• Sensitivity in target detection
• Universal protocol for PCR targets of different lengths
• Multiplex PCR of 15 targets
• Product format for direct gel loading
Request a sample of Platinum II Taq enzyme at http://bit.ly/2M4U9cw
Find other PCR enzymes at http://bit.ly/2JIPrzj
Learn more about PCR at http://bit.ly/2y2aSVo
#PCR #PCREducation #Invitrogen #InvitrogenSchoolofMolBio
Human cytomegalovirus (CMV) is a common immune-evasive herpes family virus leading to lifelong asymptomatic infection in 50 to 80% of humans. Current research evaluating the use of
TCR sequencing to predict response to immunotherapy has focused on measurements of T cell clonal expansion and TCR convergence (2,3,4) as potential predictive biomarkers for
response. Given that CMV infection has been reported to elicit large clonal proliferations of CMV reactive T cells (1), and is a source of chronic antigen stimulation, we hypothesized that CMV
infection might alter T cell repertoire features in a manner relevant to the potential biomarker use of TCR sequencing. Here we sought to identify features of CMV infection using TCRB profiling of
peripheral blood (PBL) total RNA. We identify reduced T cell evenness and elevated TCR convergence as features of chronic CMV infection.
Improvement of TMB Measurement by removal of Deaminated Bases in FFPE DNAThermo Fisher Scientific
Tumor mutational burden (TMB) is a positive predictive factor for response to immune-checkpoint inhibitors in certain types of cancer. The Oncomine™ Tumor Mutation Load Assay, a targeted next generation sequencing (NGS) assay, measures TMB (from 1.2Mb of coding region) and detects mutations in 409 cancer genes. The TMB values obtained using targeted sequencing are highly correlated with TMB measured by whole exome sequencing. FFPE preservation methods can lead to significant cytosine deamination of the isolated DNA, resulting in decreased sequencing quality. In these samples, uracils are propagated as thymines and result in false C>T substitutions. Analysis of the Oncomine™ TML Assay using Torrent Suite and Ion Reporter ™ software uniquely estimates the degree of deamination in fixed tissues by measuring C:G>T:A variants. This deamination score is used to assess quality of DNA extracted from FFPE tumor tissue. To minimize the influence
that excess deamination has on TMB results, we have incorporated a repair treatment to eliminate damaged targets and improve usable TMB values of DNA from damaged FFPE tumor tissue using Uracil-DNA glycosylase (UDG). The
Oncomine™ TML Assay for TMB on the Ion Gene Studio™ S5 systems in conjunction with a deamination score is informative and potentially predictive for the use of checkpoint inhibitors in multiple cancer types.
What can we learn from oncologists? A survey of molecular testing patternsThermo Fisher Scientific
Oncologists are increasingly incorporating NGS testing to guide targeted and immuno-oncology therapies1. Most clinical NGS testing is confined to large academic institutions and reference labs, despite the fact that most cancer patients are treated in the community settings. We therefore sought to examine molecular testing selection patterns directly from oncologists in order to better identify perceived gaps in testing and treatment paradigms
Evaluation of ctDNA extraction methods and amplifiable copy number yield usin...Thermo Fisher Scientific
The use of cell-free circulating tumor DNA (ctDNA) for non-invasive cancer testing has the potential to revolutionize the field. However, emergence of an increasing number of extraction methods and detection assays is rendering laboratory workflow development much more complex and cumbersome. The use of standardized, well characterized ctDNA control materials in human plasma could facilitate the evaluation of extraction efficiency and assay performance across platforms. In this study, we use a full process ctDNA quality control material in true human plasma to demonstrate the variability of extraction yield between different ctDNA extraction kits. We also examine the correlation between the amplifiable
copy number and DNA concentration post-extraction.
Analytical Validation of the Oncomine™ Comprehensive Assay v3 with FFPE and C...Thermo Fisher Scientific
Presented here is an analytical validation of OCAv3 at the Life Technologies Clinical Services Laboratory (LTCSL), a CAP-accredited and CLIA-certified clinical laboratory. Analytical validations provide evidence of consistently accurate and relevant sequencing results.
Novel Spatial Multiplex Screening of Uropathogens Associated with Urinary Tra...Thermo Fisher Scientific
Accurate identification of uropathogens in a timely manner is important to correctly understand urinary tract infections(UTI’s), which affects nearly 150 million people each year. The
current standard approach for detecting the UTI pathogens is culture based. This method is time consuming, has low throughput, and can lack sensitivity and/or specificity. In addition, not all uropathogens grow equally well under standard culture conditions which can result in a failure to detect the species. To address these gaps, we have developed a unique workflow from sample preparation to target identification using the nanofluidic OpenArray™ platform for spatial multiplexing of target specific assays. In this study, we tested pre-determined blinded research samples and confirmed the subset of results with orthogonal Sanger sequences.
Liquid biopsy quality control – the importance of plasma quality, sample prep...Thermo Fisher Scientific
Liquid biopsy is emerging as a non-invasive companion to traditional solid tumor biopsies. As next generation sequencing (NGS) of circulating cell-free nucleic acids (cfNA = cfDNA and cfRNA) becomes common, it’s important to understand the impact of sample preparation on quality, specificity, and sensitivity of liquid biopsy tests. Plasma samples are often limited, and may have undesirable characteristics such as lipemia or hemolysis that contribute unwanted genomic DNA (gDNA) to the sample. Low cfDNA concentration can also limit the amount available for NGS library prep. In this study, we explore the effects of suboptimal plasma and low library input on liquid biopsy NGS, and discuss various techniques for in-process quality control of cfNA samples isolated from plasma
Streamlined next generation sequencing assay development using a highly multi...Thermo Fisher Scientific
Next generation sequencing (NGS) assay development for solid tumor sequencing requires characterization of variant calling directly from formalin-fixed paraffin embedded (FFPE) tissue samples. However, cell line based FFPE and human FFPE samples only contain 2 to 20 variants, which require laboratories to invest significant resources in sample sourcing and preparation when developing assays to detect 100+ variants
Targeted T-cell receptor beta immune repertoire sequencing in several FFPE ti...Thermo Fisher Scientific
T-cell receptor beta (TCRβ) immune repertoire analysis by next-generation sequencing is a valuable tool for studies of the tumor microenvironment and potential immune responses to cancer immunotherapy. Here we describe a TCRβ sequencing assay that leverages the low sample input requirements of AmpliSeq library preparation technology to extend the capability of targeted immune repertoire sequencing to include FFPE samples which can often be degraded and in short supply
Development of Quality Control Materials for Characterization of Comprehensiv...Thermo Fisher Scientific
Targeted next-generation sequencing (NGS) panels can detect hundreds of mutations in key genes using amplification based and hybrid-capture based NGS technologies. Although NGS technology is a powerful tool, optimizing and characterizing test performance on hundreds of variants is extremely challenging, time consuming, and expensive. Samples must be sourced, variants identified and orthogonally confirmed, then quantified and diluted. This effort is then multiplied across dozens of samples, and then samples must be run over many runs and days to assess assay reproducibility, precision, sensitivity, etc. In this study, we developed a novel reference material, experimental design, and analysis pipeline that allows for highly streamlined NGS assay characterization, enabling thorough test characterization across 500+ variants within only 6 runs.
As one of the leading causes of death globally, respiratory
infections could be caused by single or multiple types of viral,
bacterial or fungal pathogens that present in the upper and
lower respiratory tract. Panel-based testing using molecular
methods to identify multiple pathogens simultaneously can
contribute to better understanding of respiratory infections.
A high-throughput approach for multi-omic testing for prostate cancer researchThermo Fisher Scientific
The proliferation of genetic testing technologies and genome-scale studies has increased our understanding of the genetic basis of complex diseases. However, this information alone tells an incomplete story of the underlying biology. Integrative approaches that combine data from multiple sources, such as the genome, transcriptome and/or proteome, can provide a more comprehensive and multi-dimensional model of complex diseases. Similarly, the integration of multiple data types in disease screening can improve our understanding of disease in populations. In a series of groundbreaking multi-omic, population-based studies of prostate cancer, researchers at the Karolinska Institutet in Stockholm, Sweden identified sets of genetic and protein biomarkers that when evaluated together with other clinical research data performed significantly better in predicting cancer risk (1,2) than the most-widely used single protein biomarker, the prostate-specific antigen (PSA).
Discover the innovations and more that led to amazing discoveries through the use of thermal cyclers. What were scientists able to accomplish? What things are important to them when selecting a thermal cycler? What do you need to advance your science?
Learn more about thermal cyclers: http://bit.ly/2Q2oPhF
See all thermal cycler offerings: http://bit.ly/2Paf1wH
A rapid library preparation method with custom assay designs for detection of...Thermo Fisher Scientific
Herein, we describe a new research method for library
preparation using the Ion AmpliSeq™ HD Library Kit with
custom assay designs from Ion AmpliSeq HD Panels for
detection of low level variants from liquid biopsy samples. This
method includes incorporation of molecular tags that enable
0.1% Limit of Detection (LOD) in cell free DNA (cfDNA) and
dual barcodes for sample identification. This method is also
applicable to formalin-fixed paraffin embedded (FFPE)
samples. The libraries can be prepared in as little as 3 hours
and are compatible for analysis with the Ion GeneStudio™ S5
system
Generation of Clonal CRISPR/Cas9-edited Human iPSC Derived Cellular Models an...Thermo Fisher Scientific
Reprogramming permits the derivation of hiPSCs from diseased patients, and allows us to model diseases in vitro. Furthermore, with the advent of CRISPR mediated genome editing, we can now mimic disease mutations in control hiPSC lines to study the biological effect of just those mutations. hiPSCs can then be differentiated into specified cell types such as neurons which can be used to develop assays for drug safety screening or can be used to model disease phenotypes in a dish to discover new drugs.
TaqMan®Advanced miRNA cDNA synthesis kit to simultaneously study expression o...Thermo Fisher Scientific
MicroRNAs (miRNA) are a class of small non-coding RNAs (approximately 21 nt long) that bind complementary sequences in target mRNAs to specifically regulate gene expression. Aberrant regulation of miRNAs and their targets has been associated with several diseases including cancer. The relationship between miRNA and mRNA has been found to be important in cancer development and progression. Simultaneous expression studies of miRNA and mRNA and detection of mutations in mRNA transcripts can be valuable in understanding molecular mechanisms that
have an underlying role in various diseases. We demonstrate the technical verification of a novel method to reverse-transcribe and pre-amplify miRNA and mRNA from sample-limiting serum research samples using the TaqMan® Advanced miRNA cDNA Synthesis Kit. Based on results from previous studies, a signature of 49 mRNA and 37 miRNA targets has been identified that may help distinguish between benign and malignant pancreatic tissues. In this study, these targets and an additional set of transcript mutations were analyzed in serum from normal and test samples. TaqMan assays for miRNA and mRNA targets and custom TaqMan Mutation Detection Assays (TMDAs) were placed on TaqMan Array Cards to facilitate investigation of several samples in a single experiment. Results demonstrate that transcript mutations can be detected and miRNA and mRNA targets can be reliably quantified from a single reverse transcription reaction. For research use only. Not for use in diagnostic purposes.
Identifying novel and druggable targets in a triple negative breast cancer ce...Thermo Fisher Scientific
In this study, we developed a CRISPR/Cas9-based high throughput loss-of-function screen for identifying target genes responsible for the tumor proliferation and growth in TNBC. Our initial focus was to identify essential kinases in MDA-MB-231 cell line using the Invitrogen™ LentiArray™ Human Kinase CRISPR Library, which targets 840 kinases with up to 4 different gRNAs per protein kinase for complete gene knockout. This functional screen identified over 90 protein kinases that are essential for cell viability and cell proliferation. Ten of these hits (CDK1, CDK2, CDK8, CDK10, CDK11A, CDK19, CDK19, CDC7, EPHA2 and WEE1) are well-known targets validated in the literature. Currently, we are in the process validating the novel hits through target gene sequencing, western blotting and target specific small molecule kinase inhibitors.
Evidence for antigen-driven TCRβ chain convergence in the melanoma-infiltrati...Thermo Fisher Scientific
T cell convergence refers to the phenomenon whereby antigen-driven selection enriches for T cell receptors (TCRs) having a shared antigen specificity but different amino acid or
nucleotide sequence. T cell recruitment and expansion within the tumor microenvironment (TME) may be directed by responses to tumor neoantigen, suggesting that elevated T
cell convergence could be a general feature of the tumor infiltrating T cell repertoire. Here we use the Ion AmpliSeq™ Immune Repertoire Assay Plus – TCRβ to evaluate evidence
for T cell convergence within melanoma tumor biopsy research samples from a set of 63 subjects plus peripheral blood leukocytes (PBL) from four healthy subjects. We find that the melanoma TME is highly enriched for convergent TCRs compared to healthy donor peripheral blood. We discuss the potential use of TCR convergence as a liquid biopsy compatible predictive biomarker for immunotherapy response.
Analytical performance of a novel next generation sequencing assay for Myeloi...Thermo Fisher Scientific
To support clinical and translational research into precision oncology strategies for myeloid cancers, a next-generation sequencing (NGS) assay was developed to detect common and relevant somatic alterations. To define gene targets that were recurrently altered in myeloid cancers and relevant for clinical and translational research, an extensive survey of investigators at hematology oncology research labs was performed.
State of ICS and IoT Cyber Threat Landscape Report 2024 previewPrayukth K V
The IoT and OT threat landscape report has been prepared by the Threat Research Team at Sectrio using data from Sectrio, cyber threat intelligence farming facilities spread across over 85 cities around the world. In addition, Sectrio also runs AI-based advanced threat and payload engagement facilities that serve as sinks to attract and engage sophisticated threat actors, and newer malware including new variants and latent threats that are at an earlier stage of development.
The latest edition of the OT/ICS and IoT security Threat Landscape Report 2024 also covers:
State of global ICS asset and network exposure
Sectoral targets and attacks as well as the cost of ransom
Global APT activity, AI usage, actor and tactic profiles, and implications
Rise in volumes of AI-powered cyberattacks
Major cyber events in 2024
Malware and malicious payload trends
Cyberattack types and targets
Vulnerability exploit attempts on CVEs
Attacks on counties – USA
Expansion of bot farms – how, where, and why
In-depth analysis of the cyber threat landscape across North America, South America, Europe, APAC, and the Middle East
Why are attacks on smart factories rising?
Cyber risk predictions
Axis of attacks – Europe
Systemic attacks in the Middle East
Download the full report from here:
https://sectrio.com/resources/ot-threat-landscape-reports/sectrio-releases-ot-ics-and-iot-security-threat-landscape-report-2024/
Software Delivery At the Speed of AI: Inflectra Invests In AI-Powered QualityInflectra
In this insightful webinar, Inflectra explores how artificial intelligence (AI) is transforming software development and testing. Discover how AI-powered tools are revolutionizing every stage of the software development lifecycle (SDLC), from design and prototyping to testing, deployment, and monitoring.
Learn about:
• The Future of Testing: How AI is shifting testing towards verification, analysis, and higher-level skills, while reducing repetitive tasks.
• Test Automation: How AI-powered test case generation, optimization, and self-healing tests are making testing more efficient and effective.
• Visual Testing: Explore the emerging capabilities of AI in visual testing and how it's set to revolutionize UI verification.
• Inflectra's AI Solutions: See demonstrations of Inflectra's cutting-edge AI tools like the ChatGPT plugin and Azure Open AI platform, designed to streamline your testing process.
Whether you're a developer, tester, or QA professional, this webinar will give you valuable insights into how AI is shaping the future of software delivery.
The Art of the Pitch: WordPress Relationships and SalesLaura Byrne
Clients don’t know what they don’t know. What web solutions are right for them? How does WordPress come into the picture? How do you make sure you understand scope and timeline? What do you do if sometime changes?
All these questions and more will be explored as we talk about matching clients’ needs with what your agency offers without pulling teeth or pulling your hair out. Practical tips, and strategies for successful relationship building that leads to closing the deal.
Smart TV Buyer Insights Survey 2024 by 91mobiles.pdf91mobiles
91mobiles recently conducted a Smart TV Buyer Insights Survey in which we asked over 3,000 respondents about the TV they own, aspects they look at on a new TV, and their TV buying preferences.
Epistemic Interaction - tuning interfaces to provide information for AI supportAlan Dix
Paper presented at SYNERGY workshop at AVI 2024, Genoa, Italy. 3rd June 2024
https://alandix.com/academic/papers/synergy2024-epistemic/
As machine learning integrates deeper into human-computer interactions, the concept of epistemic interaction emerges, aiming to refine these interactions to enhance system adaptability. This approach encourages minor, intentional adjustments in user behaviour to enrich the data available for system learning. This paper introduces epistemic interaction within the context of human-system communication, illustrating how deliberate interaction design can improve system understanding and adaptation. Through concrete examples, we demonstrate the potential of epistemic interaction to significantly advance human-computer interaction by leveraging intuitive human communication strategies to inform system design and functionality, offering a novel pathway for enriching user-system engagements.
Let's dive deeper into the world of ODC! Ricardo Alves (OutSystems) will join us to tell all about the new Data Fabric. After that, Sezen de Bruijn (OutSystems) will get into the details on how to best design a sturdy architecture within ODC.
"Impact of front-end architecture on development cost", Viktor TurskyiFwdays
I have heard many times that architecture is not important for the front-end. Also, many times I have seen how developers implement features on the front-end just following the standard rules for a framework and think that this is enough to successfully launch the project, and then the project fails. How to prevent this and what approach to choose? I have launched dozens of complex projects and during the talk we will analyze which approaches have worked for me and which have not.
Neuro-symbolic is not enough, we need neuro-*semantic*Frank van Harmelen
Neuro-symbolic (NeSy) AI is on the rise. However, simply machine learning on just any symbolic structure is not sufficient to really harvest the gains of NeSy. These will only be gained when the symbolic structures have an actual semantics. I give an operational definition of semantics as “predictable inference”.
All of this illustrated with link prediction over knowledge graphs, but the argument is general.
GraphRAG is All You need? LLM & Knowledge GraphGuy Korland
Guy Korland, CEO and Co-founder of FalkorDB, will review two articles on the integration of language models with knowledge graphs.
1. Unifying Large Language Models and Knowledge Graphs: A Roadmap.
https://arxiv.org/abs/2306.08302
2. Microsoft Research's GraphRAG paper and a review paper on various uses of knowledge graphs:
https://www.microsoft.com/en-us/research/blog/graphrag-unlocking-llm-discovery-on-narrative-private-data/
From Daily Decisions to Bottom Line: Connecting Product Work to Revenue by VP...
Ion Proton™ Sequencer - The Benchtop Genome Center
1. Ion Proton™ System
y
January 2012
The content provided herein may relate to products that have not
been officially released and is subject to change without notice.
2. Highly Disruptive Technologies
E
Empower E Everyone
Main Frame Mini Computer Personal Computer
Sanger Sequencing Next‐Gen Sequencing Ion Semiconductor Sequencing
Technology generations are defined by who can use them
2
4. Ion’s Semiconductor Chip Sees Chemistry
Biological Information Ion Semiconductor Chip Digital Information
Leverages $1 Trillion investment and $50 Billion annual spend
4
5. Ion PGM™ Sequencer:
The Fastest Selling Sequencer in the World
• Speed:1.5
Speed:1 5 hour runs
• Scalability:10 Mb to 1 Gb
• Simplicity: Automated
workflows, benchtop
convenience
• Affordable
Aff d bl
5
6. The Promise of Semiconductor Sequencing
First 100-Fold Scaling Delivered and More
100 Fold
Achieved i 2011
A hi d in
• 100-fold scaling and 200 bp kits,
Ion 318™
Chip*
525 base perfect reads achieved
• Breakthrough Ion AmpliSeq™ app,
microbial and RNA-seq apps
Ion 316™
Chip • 5,000 member Ion Community
Ion 314™ 2012 Roadmap
Chip
• 2 x 200 paired end kit, 400 bp kits
• Custom and fixed AmpliSeq™ panels
• FDA submission and CE-IVD
certification
6 The content provided herein may relate to products that have not
been officially released and is subject to change without notice.
7. Introducing Ion Proton™ Chips
The Next 100-Fold Scaling
100 Fold
7 The content provided herein may relate to products that have not
been officially released and is subject to change without notice.
8. $500 Exome and $1,000 Genome
Sequencing in a Few Hours on the Benchtop
Ion Proton™ I Chip Ion Proton™ II Chip
2 human exomes 1 human genome
165 million wells 660 million wells
$1,000 per run $1,000 per run
Highest Throughput
8 The content provided herein may relate to products that have not
been officially released and is subject to change without notice.
9. Introducing the Ion Proton™ Sequencer
The Benchtop Genome Center
9 The content provided herein may relate to products that have not
been officially released and is subject to change without notice.
10. Introducing the Ion Proton™ Sequencer
The Benchtop Genome Center
10 The content provided herein may relate to products that have not
been officially released and is subject to change without notice.
11. Introducing the Ion Proton™ Sequencer
The Benchtop Genome Center
11 The content provided herein may relate to products that have not
been officially released and is subject to change without notice.
12. Introducing the Ion Proton™ Sequencer
The Benchtop Genome Center
• Supports Ion Proton™ I and
Proton
Proton™ II chips
• $149K List Price (USD)
– $99K for Ion PGM™ owners
• State-of-the-art electronics to
support highest throughput
12 The content provided herein may relate to products that have not
been officially released and is subject to change without notice.
13. …and Rack-Mountable!
Broad, Baylor,
Broad Baylor and Yale have already
signed up for this configuration
13 The content provided herein may relate to products that have not
been officially released and is subject to change without notice.
14. Harnessing a Decade of Moore’s Law in
O L
One Leap…
Nature 475, 348 352 (21 July 2011)
475 348–352
Ion Proton™ I Chip: 165 million wells
(>100-fold
( 100 fold more wells than Ion 314™ Chip)
314
14 The content provided herein may relate to products that have not
been officially released and is subject to change without notice.
15. …While Seamlessly Scaling Ion’s PostLight™
Sequencing Ch i t
S i Chemistry
Ion 314™ Chip Signal Ion Proton™ I Chip Signal
Nucleotide Incorporation Signal
Signal,
Same Signal Same Speed
Internally generated R&D data shown
15 The content provided herein may relate to products that have not
been officially released and is subject to change without notice.
16. Maintaining 200 Base Read Lengths
200 Base Q20 Reads on Ion Proton™ I Chip
TCTTCTTCTGGCTGCCAGCACGCCGGTTGTAGTGGGATCTCTTCGCGATC
||||||||||||||||||||||||||||||||||||||||||||||||||
TCTTCTTCTGGCTGCCAGCACGCCGGTTGTAGTGGGATCTCTTCGCGATC
1 10 20 30 40 50
AAACGCCAGATCACCCCCGTTAACCACTTCAGAACCGTGGGTGATGACCT
||||||||||||||||||||||||||||||||||||||||||||||+|||
AAACGCCAGATCACCCCCGTTAACCACTTCAGAACCGTGGGTGATG-CCT
51 60 70 80 90 100
TTGAAATCGAATCAGGTTGGTATCGCACAGATGCGACGGCACCACATTCT
|||||||||||+||||||||||||||||||||||||||||||||||||||
TTGAAATCGAA CAGGTTGGTATCGCACAGATGCGACGGCACCACATTCT
TTGAAATCGAA-CAGGTTGGTATCGCACAGATGCGACGGCACCACATTCT
101 110 120 130 140 150
GCATCGCGCTGAACATCGTCTCGATACGCCCTGGATAACGTTTATCCCAG
||||||||||||||||||||||||||||||||||||||||||||||||||
GCATCGCGCTGAACATCGTCTCGATACGCCCTGGATAACGTTTATCCCAG
151 160 170 180 190 200
TCA
|||
TCA
201
Internally generated R&D data shown
16 The content provided herein may relate to products that have not
been officially released and is subject to change without notice.
17. Single Day Workflow with Highest Throughput
Ion Kits Ion Proton™ Ion Proton™ Sequencer Proton™ Torrent Server
OneTouch S t
O T h System
17 The content provided herein may relate to products that have not
been officially released and is subject to change without notice.
18. Streamlined Bioinformatics Infrastructure
Server Room & Informaticists in a Box and in the Cloud
Ion Reporter™
Solution
Proton
Proton™ Torrent Server
and Torrent Suite Software
18 The content provided herein may relate to products that have not
been officially released and is subject to change without notice.
19. Overcoming Data Bottlenecks
Full Genomes in Ion Reporter™
p High Data
g
Hours vs. Weeks Solution Quality
More uniform coverage
Single genome Flexible cloud-based
enables higher quality
sequencing in hours solution to manage
manage,
variant calls with less raw
greatly eases analysis annotate, and archive
data. Longer reads
bottleneck (vs. batch- variants of interest for
enable better mappability
processing) future interpretation
with less raw data
19 The content provided herein may relate to products that have not
been officially released and is subject to change without notice.
20. Ion Proton™ System Availability
January 2012 Ion Proton System available for quotes
Proton™
Ion Proton™ I Chip to commence shipment
Mid-2012 (Ion Proton™ II Chip to be available 6 months later)
Early Access for 4-unit rack-mounted configuration
4 unit rack mounted
Unrestricted launch of Ion Proton™ Sequencer and
End of Q3:2012
standalone Proton Torrent™ Server to commence
20 The content provided herein may relate to products that have not
been officially released and is subject to change without notice.
21. Ion Semiconductor Sequencing
Rapid,
Rapid Benchtop Sequencing for All
1.25”
1”
Genes Genomes
Ion 3 Series Chips
3-Series Ion Proton™ Chips
Ion PGM™ Sequencer Ion Proton™ Sequencer
21 The content provided herein may relate to products that have not
been officially released and is subject to change without notice.
22. Unprecedented Scaling Every 6 Months
22 The content provided herein may relate to products that have not
been officially released and is subject to change without notice.
23. Enabling All Applications
23 The content provided herein may relate to products that have not
been officially released and is subject to change without notice.
24. 5500 Wildfire
24 The content provided herein may relate to products that have not
been officially released and is subject to change without notice.
25. Wildfire Offered to Existing 5500 Customers
Mid-2012 Delivery
Wildfire simplifies workflow and improves economics while
retaining ultra high accuracy and p y p
g g y pay-per-lane sequencing
q g
1.Simpler Workflow: 2 hour on flowchip template preparation
2.Lower Price / Gb: $25 / Gb guaranteed
3.Higher Throughput:
g g p > 20 Gb / day throughput
y g p
25 The content provided herein may relate to products that have not
been officially released and is subject to change without notice.
26. Purchasing Options for 5500 and
SOLiD C t
Customers
• Ion Proton™ Sequencer + Wildfire upgrade
q pg
(discounted package for 5500 customers)
• Ion Proton™ Sequencer + 5500 Wildfire
(discounted package for SOLiD customers)
• Ion Proton™ Sequencer
(discounted, standalone for 5500/SOLiD)
• Wildfire upgrade
(list price, standalone for 5500/SOLiD)
26 The content provided herein may relate to products that have not
been officially released and is subject to change without notice.
27. All products mentioned in this presentation are for Research Use Only,
not i t d d f any animal or h
t intended for i l human th therapeutic or di
ti diagnostic use.
ti
27 Confidential and Proprietary—DO NOT DUPLICATE